A Sharp Decline in AstraZeneca Shares

A Sharp Decline in AstraZeneca Shares During the coronavirus epidemic, a sharp decline occurred in the shares of AstraZeneca, one of the pharmaceutical companies that came up with vaccination studies. The company experienced a sharp decline after the announcement of the highest amount purchase agreement in its history. Stocks of AstraZeneca Plc fell sharply after the confirmation that it will buy Alexion Pharmaceuticals Inc. for $ 39 billion in cash and shares. With this agreement, AstraZeneca will be the largest acquisition ever in history. After the announcement, stocks fell 9.2 percent to the lowest level seen since April. The UK-based pharmaceutical company has been under an ongoing pressure recently due to question marks regarding the effectiveness of the coronavirus vaccine and its final stage experiments. The depreciation of AstraZeneca stocks fell to 5.7 percent at 8:10 am London time. The bid announced on Saturday shows a 45 percent premium compared to Alexion's closing price on Friday.